Methods of treating osteonecrosis with LLP2A-bisphosphonate compounds
AssigneeThe Regents of the University of California
InventorsNancy Lane, Wei Yao
Life of this patent
Estimating the term…
Abstract
Methods of treating osteonecrosis in a subject are provided. In some embodiments, the method comprises administering to a subject having or suspected of having osteonecrosis a pharmaceutical composition comprising a conjugate of an LLP2A peptidomimetic ligand and a bisphosphonate drug. In some embodiments, the pharmaceutical composition comprises a conjugate of LLP2A and alendronate (LLP2A-Ale). In some embodiments, the method further comprises administering exogenous mesenchymal stem cells.
Claims13
A method of treating osteonecrosis in a subject classified as having Stage 2, 3, or 4 disease by the Ficat classification system, the method comprising:
- (a) detecting in the subject at least one osteonecrotic lesion having a size of more than 5 cm2 in at least one bone;
- wherein the osteonecrosis is traumatic osteonecrosis or glucocorticoid-induced osteonecrosis or alcohol-induced osteonecrosis, and
- (b) administering locally to the subject a pharmaceutical composition comprising a conjugate of LLP2A and Alendronate (“LLP2A-Ale”) having the formula:
A method of increasing vascular density in an osteonecrotic tissue in a subject classified as having Stage 2, 3, or 4 disease by the Ficat classification system, the method comprising:
- (a) detecting in the subject at least one osteonecrotic lesion having a size of more than 5 cm2 in at least one bone, wherein the osteonecrosis is traumatic osteonecrosis or glucocorticoid-induced osteonecrosis or alcohol-induced osteonecrosis, and
- (b) administering locally to the subject a pharmaceutical composition comprising a conjugate of LLP2A and Alendronate (“LLP2A-Ale”) having the formula:
A method of preventing or reducing cell death in an osteonecrotic tissue in a subject classified as having Stage 2, 3, or 4 disease by the Ficat classification system, the method comprising:
- (a) detecting in the subject at least one osteonecrotic lesion having a size of more than 5 cm2 in at least one bone;
- wherein the osteonecrosis is traumatic osteonecrosis or glucocorticoid-induced osteonecrosis or alcohol-induced osteonecrosis;
- and
- (b) administering locally to the subject a pharmaceutical composition comprising a conjugate of LLP2A and Alendronate (“LLP2A-Ale”) having the formula:
Dependencies are inferred from the claim text.